Table 3.
Enrollment, Study Design, Completion Date, Collaborators, and Key Locations of Current Clinical Trials at Phase I for Prostate Cancer, 2022 (as of 5 December 2022).
| No. | NCT Number | Phases | Age | N | Study Type and Design | Completion Date | Collaborators | Locations |
|---|---|---|---|---|---|---|---|---|
| 1 | NCT04301414 | Early Phase 1 | ≥18 years | 24 | Interventional; Randomized, Open Label, Treatment | May-24 | Matthew Dallos; Bristol-Myers Squibb; Ferring Pharmaceuticals; Columbia University | United States |
| 2 | NCT04615845 | Phase 1 | 20–80 years | 10 | Interventional; Single Group, Open Label, Treatment | Dec-22 | Pharmicell Co., Ltd. | Republic of Korea |
| 3 | NCT02740985 | Phase 1 | 18–130 years | 313 | Interventional; Non-Randomized, Open Label, Treatment | 28-Dec-22 | AstraZeneca | Various, United States |
| 4 | NCT04388852 | Phase 1 | ≥18 years | 80 | Interventional; Single Group, Open Label, Treatment | 31-Jan-23 | M.D. Anderson Cancer Center; National Cancer Institute (NCI) | United States |
| 5 | NCT04660929 | Phase 1 | ≥18 years | 18 | Interventional; Single Group, Open Label, Treatment | Feb-23 | Carisma Therapeutics Inc | Various, United States |
| 6 | NCT01140373 | Phase 1 | ≥18 years | 13 | Interventional; Single Group, Open Label, Treatment | Jun-23 | Memorial Sloan Kettering Cancer Center; United States Department of Defense | United States |
| 7 | NCT03177460 | Phase 1 | ≥18 years | 33 | Interventional; Non-Randomized, Open Label, Treatment | 29-Jun-23 | M.D. Anderson Cancer Center; National Cancer Institute (NCI) | United States |
| 8 | NCT02009449 | Phase 1 | ≥18 years | 350 | Interventional; Non-Randomized, Single Group, Open Label, Treatment | 17-Nov-23 | Eli Lilly and Company; ARMO BioSciences | Various, United States |
| 9 | NCT04077021 | Phase 1 | ≥18 years | 22 | Interventional; Non-Randomized, Open Label, Treatment | Dec-23 | Calibr, a division of Scripps Research | United States |
| 10 | NCT04580485 | Phase 1 | ≥18 years | 230 | Interventional; Non-Randomized, Parallel Assignment, Open Label, Treatment | 29-Dec-23 | Incyte Corporation | Various, United States, Belgium, France, Italy, Spain, United Kingdom |
| 11 | NCT03556228 | Phase 1 | ≥18 years | 74 | Interventional; Sequential Assignment, Open Label, Treatment | Jun-24 | VM Oncology, LLC | Various, United States |
| 12 | NCT03805594 | Phase 1 | ≥18 years | 43 | Interventional; Non-Randomized, Open Label, Treatment | 30-Apr-24 | University of California, San Francisco; Prostate Cancer Foundation; National Cancer Institute (NCI) | United States |
| 13 | NCT05077098 | Phase 1 | 18–99 Years | 21 | Interventional; Single Group, Open Label, Treatment | Sep-24 | Mark Stein; Columbia University | United States |
| 14 | NCT03792841 | Phase 1 | ≥18 years | 212 | Interventional; Non-Randomized, Open Label, Treatment | 16-May-25 | Amgen | Various, Australia, Austria, Belgium, Canada, Japan, Singapore, Taiwan |
| 15 | NCT04477512 | Phase 1 | ≥18 years | 22 | Interventional; Non-Randomized, Open Label, Treatment | 31-Aug-25 | Washington University School of Medicine; Bristol-Myers Squibb; Exelixis | United States |
| 16 | NCT04514484 | Phase 1 | ≥18 years | 18 | Interventional; Single Group, Open Label, Treatment | 2-Nov-25 | National Cancer Institute (NCI) | United States |
| 17 | NCT05354375 | Phase 1 | 18–75 Years | 20 | Interventional; Single Group, Open Label, Treatment | 30-Nov-26 | The Affiliated Hospital of Xuzhou Medical University; Xuzhou Medical University | China |
| 18 | NCT04221542 | Phase 1 | ≥18 years | 459 | Interventional; Non-Randomized, Open Label, Treatment | 9-Aug-27 | Amgen | Various, United States, Australia, Japan, Korea, Taiwan |
| 19 | NCT05010200 | Phase 1 | ≥18 years | 27 | Interventional; Non-Randomized, Open Label, Prevention | Dec-27 | Ashutosh Kumar Tewari; Icahn School of Medicine at Mount Sinai | United States |